Medication info

Pedia Injection (Ibuprofen)

Prescription medicationInjectionsInjection
Ingredient · strength
Ibuprofen›10mg / 1mL
Manufacturer / importer
SAMOH PHARM CO., LTD.
Appearance
An injection in a colorless to pale yellow liquid contained in a colorless transparent glass ampoule
Packaging
10mg/2mL ampoule x 4
Approval status
Active

MFDS item code 201103928 · Approved 2011.06.22 · Insurance code 659700881

Summary

Main use
Treatment of clinically significant patent ductus arteriosus in preterm infants born before 34 weeks of gestation
Who receives it
Adults · Children
Adult administration
This medicine is administered only via intravenous infusion. It is preferable to administer it without dilution over 15 minutes, and if necessary, the infusion volume can be adjusted using 9mg/mL (0.9%) normal saline or 50mg/mL (5%) dextrose solution. Total infusion volume should consider the total fluid administered for the day.
Child administration
For intravenous infusion only. Treatment with this medicine must be carried out only in a neonatal intensive care unit under the supervision of an experienced neonatologist. As a course of treatment, administer 3 intravenous infusions at 24-hour intervals. The first infusion should be administered no earlier than 6 hours after birth. Adjust the ibuprofen dose according to body weight as follows: - First infusion: 10mg/kg - Second and third infusions: 5mg/kg If the ductus arteriosus has not closed or has reopened 48 hours after the final infusion, a second course of the 3-dose regimen above may be administered. If there is no change in the condition after the second course of treatment, surgery for patent ductus arteriosus may be required. Method of infusion: This medicine should preferably be infused undiluted over 15 minutes. If necessary, the infusion volume may be adjusted using 9mg/mL(0.9%) sodium chloride injection or 50mg/mL(5%) glucose injection. Discard any remaining solution. Consider the total daily fluid intake when calculating the total infusion volume. If anuria or oliguria occurs after the first or second dose, withhold the next dose until urine output returns to normal.

Ingredients

Importer
SAMOH PHARM CO., LTD.

Efficacy & effects

Treatment of clinically significant patent ductus arteriosus in preterm infants born before 34 weeks of gestation

  • Patent ductus arteriosus
View approved original text

This medication is used to treat hemodynamically significant patent ductus arteriosus in premature infants born before 34 weeks of gestation.

How it is given

Adult administration

This medicine is administered only via intravenous infusion. It is preferable to administer it without dilution over 15 minutes, and if necessary, the infusion volume can be adjusted using 9mg/mL (0.9%) normal saline or 50mg/mL (5%) dextrose solution. Total infusion volume should consider the total fluid administered for the day.

Child administration

For intravenous infusion only. Treatment with this medicine must be carried out only in a neonatal intensive care unit under the supervision of an experienced neonatologist. As a course of treatment, administer 3 intravenous infusions at 24-hour intervals. The first infusion should be administered no earlier than 6 hours after birth. Adjust the ibuprofen dose according to body weight as follows: - First infusion: 10mg/kg - Second and third infusions: 5mg/kg If the ductus arteriosus has not closed or has reopened 48 hours after the final infusion, a second course of the 3-dose regimen above may be administered. If there is no change in the condition after the second course of treatment, surgery for patent ductus arteriosus may be required. Method of infusion: This medicine should preferably be infused undiluted over 15 minutes. If necessary, the infusion volume may be adjusted using 9mg/mL(0.9%) sodium chloride injection or 50mg/mL(5%) glucose injection. Discard any remaining solution. Consider the total daily fluid intake when calculating the total infusion volume. If anuria or oliguria occurs after the first or second dose, withhold the next dose until urine output returns to normal.

Precautions

This medication must be administered only after conducting an echocardiogram to confirm the absence of pulmonary hypertension and duct-dependent congenital heart disease in newborns with cardiac function issues. It should not be used prophylactically in premature infants less than 28 weeks gestational age within the first three days of life, as there is a risk of developing pulmonary hypertension and hypoxemia. It should not be used in newborns with high bilirubin levels, as it may increase bilirubin concentrations in the blood and raise the risk of encephalopathy. Care must be taken when assessing for infections, as this drug may mask symptoms of infection. Injection should be done carefully to prevent tissue irritation or extravasation of the drug. As this drug suppresses platelet function, careful observation for signs of bleeding is necessary. Use with aminoglycoside antibiotics may alter blood drug concentrations, so close monitoring via blood tests is required. It may affect renal and gastrointestinal function, necessitating frequent assessment of these organs. Severe skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis may occur; discontinue administration immediately if a skin rash or abnormal symptoms appear. This medication should not be given to newborns with the following conditions: life-threatening infections, active bleeding, thrombocytopenia, severe renal dysfunction, certain congenital heart diseases, necrotizing enterocolitis, and hypersensitivity to this medication or its additives. Various adverse reactions may occur in multiple organ systems, including the blood and lymphatic systems, nervous system, respiratory system, gastrointestinal tract, kidneys, and skin during treatment with this drug, thus requiring careful monitoring of the patient's condition. This medication may interact with diuretics, anticoagulants, corticosteroids, nitric oxide, other NSAIDs, and aminoglycoside antibiotics, so caution is advised when used concurrently with these drugs. In cases of overdose, central nervous system depression, seizures, gastrointestinal disturbances, hypotension, renal dysfunction, and other complications may occur; appropriate supporting treatment is necessary. Check the condition of the ampoule before use, use it only once, and discard any remaining medication. When disinfecting the ampoule, do not use chlorhexidine; instead, use 60% ethanol or 70% isopropyl alcohol, and allow to dry completely after disinfection. During administration, infuse intravenously over 15 minutes without dilution, and use normal saline or dextrose solution to adjust the infusion rate. Care must be taken to avoid contact with acidic solutions, and it is recommended to flush the infusion line before and after administration. Discard any remaining medication after opening the ampoule and use it immediately to prevent microbial contamination.

Side effects

Respiratory and renal adverse reactions, pulmonary hypertension, severe hypoxemia, increased risk of bilirubin encephalopathy, symptoms of bleeding, thrombocytopenia, neutropenia, intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia, pulmonary hemorrhage, hypoxemia, necrotizing enterocolitis, intestinal perforation, gastrointestinal bleeding, gastric perforation, decreased urine output, fluid retention, hematuria, acute renal failure, renal tubular acidosis, hypokalemia, increased serum creatinine, decreased serum sodium, acute generalized exanthematous pustulosis, drug reaction (DRESS) syndrome, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, CNS depression, seizures, gastrointestinal disturbances, bradycardia, hypotension, apnea, renal function abnormalities, coma, metabolic acidosis, transient renal failure, aspiration pneumonia, apneic episodes

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container to prevent air entry, at a temperature between 1°C and 30°C at room temperature. This storage will help maintain the effectiveness of the medication.

Appearance and packaging

Appearance

An injection in a colorless to pale yellow liquid contained in a colorless transparent glass ampoule

Package unit

10mg/2mL ampoule x 4

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.